Salvage treatment for patients with acute myelogenous leukemia treated after intensive induction therapy by daunorubicin.

被引：0
|
作者：
Dobashi, N
Usui, N
Asai, O
Yano, S
Uno, S
Watanabe, H
Katori, M
Yahagi, Y
Nagamine, M
Saito, T
Yamaguchi, Y
Kasama, K
Tajima, N
Yamazaki, H
Kobayashi, T
Kuraishi, Y
机构：
[1] Jikei Univ Hosp, Dept Hematol & Oncol, Tokyo, Japan
[2] Jikei Univ, Sch Med, Dept Internal Med 3, Tokyo, Japan
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3897
引用
收藏
页码：209B / 209B
页数：1
相关论文
共 50 条
  • [41] DOSE-INTENSIVE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA - IMPROVED SURVIVAL
    SCHILLER, G
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) : 1828 - 1829
  • [42] Remission induction therapy in newly diagnosed acute myelogenous leukemia.
    Prielser, HD
    Venugopal, P
    Gregory, SA
    Robin, E
    Slivnick, D
    Galvez, A
    Adler, S
    Manson, S
    Jajeh, A
    Raza, A
    BLOOD, 2000, 96 (11) : 325A - 325A
  • [43] AGE ADAPTED INDUCTION AND INTENSIFIED CONSOLIDATION THERAPY IN ACUTE MYELOGENOUS LEUKEMIA
    KURRLE, E
    EHNINGER, G
    FREUND, M
    HEIL, G
    HOELZER, D
    LINK, H
    MITROU, PS
    ONKOLOGIE, 1986, 9 (03): : 141 - 143
  • [44] Dexamethasone during Leukemia Induction Therapy to Reduce Incidence of Acute Myelogenous Leukemia Relapse
    Sidebottom, Ashley
    Otiker, Hannah
    Teegavarapu, Purnima Sravanti
    Rivero, Gustavo
    Hwang, Grace
    BLOOD, 2022, 140 : 9032 - 9033
  • [45] Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy
    Medeot, Marta
    Tiribelli, Mario
    Patriarca, Francesca
    Sperotto, Alessandra
    Geromin, Antonella
    Fanin, Renato
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (09) : 933 - 934
  • [46] Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem
    Latagliata, R
    Petti, MC
    Fenu, S
    Mancini, M
    Spiriti, MAA
    Breccia, M
    Brunetti, GA
    Avvisati, G
    Lo Coco, F
    Mandelli, F
    BLOOD, 2002, 99 (03) : 822 - 824
  • [47] A DOSE-INTENSIVE REGIMEN OF DAUNORUBICIN AND CYTARABINE AS THE INITIAL PHASE OF THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA IN BLAST CRISIS
    KOUIDES, PA
    ROWE, JM
    BLOOD, 1994, 84 (10) : A147 - A147
  • [48] Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia
    Clavio, M
    Pierri, I
    Venturino, C
    Garrone, A
    Canepa, L
    Miglino, M
    Varaldo, R
    Ballerini, F
    Michelis, GL
    Balocco, M
    Abdall, N
    Gatto, S
    Gobbi, M
    LEUKEMIA & LYMPHOMA, 2004, 45 (12) : 2527 - 2530
  • [49] Administration Schedule of Daunorubicin for Elderly Patients with Acute Myelogenous Leukemia: A Single-institute Experience
    Dobashi, Nobuaki
    Usui, Noriko
    Yano, Shingo
    Yahagi, Yuichi
    Takei, Yutaka
    Sugiyama, Katsuki
    Takahara, Shinobu
    Ogasawara, Yoji
    Yamaguchi, Yuko
    Saito, Takeshi
    Yokoyama, Hiroki
    Aiba, Keisuke
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (06) : 820 - 824
  • [50] STUDY OF TREATMENT OF THERAPY-RELATED ACUTE MYELOGENOUS LEUKEMIA
    HUANG, XX
    EXPERIMENTAL HEMATOLOGY, 1994, 22 (08) : 761 - 761
12345